MYGN - Myriad Genetics, Inc.
After hours:
| Previous Close | 23.43 |
| Open | 22.86 |
| Bid | 21.39 x 800 |
| Ask | 23.75 x 800 |
| Day's Range | 21.56 - 23.06 |
| 52 Week Range | 13.92 - 28.18 |
| Volume | |
| Avg. Volume | 594,973 |
| Market Cap | 1.832B |
| Beta (5Y Monthly) | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Shareholders in Myriad Genetics (NASDAQ:MYGN) have lost 44%, as stock drops 3.8% this past week
The main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results...
- Zacks
Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio
Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.
- Investing.com
4 big analyst picks: Battered regional banks becoming buys
Investing.com -- Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: an Outperform initiation at Zions Bancorp and upgrades at KeyCorp, Greenhill, and Myriad Genetics.
- Zacks
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.
- Simply Wall St.
Myriad Genetics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Myriad Genetics ( NASDAQ:MYGN ) First Quarter 2023 Results Key Financial Results Revenue: US$181.2m (up 9.9% from 1Q...
- Zacks
Myriad Genetics (MYGN) Lags Q1 Earnings, Updates '23 View
Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.
- Thomson Reuters StreetEvents
Q1 2023 Myriad Genetics Inc Earnings Call
Q1 2023 Myriad Genetics Inc Earnings Call
- Zacks
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -10.53% and 5.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Myriad Genetics (MYGN) Gets Permit to Expand Tumor Testing
Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.
- Zacks
Myriad Genetics' (MYGN) New Pact to Boost Precision Medicine
Myriad Genetics' (MYGN) latest program will increase access to affordable genetic testing. It will also aid in identifying and elevating high-risk patient care.
- Zacks
Myriad Genetics' (MYGN) New Pact to Extend HRD Testing Access
Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.
- Simply Wall St.
A Look At The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Myriad Genetics fair value estimate is US$19.13 With US$22.90...
- Zacks
Myriad Genetics (MYGN) Q4 Earnings Top, Gross Margin Falls
Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.
- Thomson Reuters StreetEvents
Q4 2022 Myriad Genetics Inc Earnings Call
Q4 2022 Myriad Genetics Inc Earnings Call
- Zacks
Myriad Genetics (MYGN) Reports Q4 Loss, Tops Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 25% and 5.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind
Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.
- Simply Wall St.
Further weakness as Myriad Genetics (NASDAQ:MYGN) drops 5.5% this week, taking five-year losses to 51%
Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to...
- Zacks
Halozyme Therapeutics (HALO) Up 16.2% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment
Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.
- Motley Fool
Why Shares of Myriad Genetics Dropped 24% This Week
What happened Shares of Myriad Genetics (NASDAQ: MYGN), a genetic-testing and precision-medicine biotech company, were down more than 24% this week as of Thursday, according to data from S&P Global Intelligence.
- Zacks
Myriad Genetics (MYGN) Q3 Earnings Miss, Gross Margin Falls
Myriad Genetics (MYGN) hereditary cancer testing volume returns to growth in the third quarter. GeneSight comes up with yet another strong performance.
- Zacks
Myriad Genetics (MYGN) Reports Q3 Loss, Lags Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -375% and 9.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Novavax (NVAX) to Report Q3 Results: Wall Street Expects Earnings Growth
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Here's Why Investors Should Hold Myriad Genetics (MYGN) Now
Myriad Genetics' (MYGN) expansion across the globe, banking on myChoiceCDx test sales, seems impressive.
- Zacks
Myriad Genetics (MYGN) Gets Extensive Coverage for BRACAnalysis
Myriad Genetics' (MYGN) BRACAnalysis gained expanded coverage from MHLW to identify breast cancer patients who are eligible for treatment with Lynparza in Japan.
